Ontuxizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ontuxizumab
Monoclonal antibody
Type Whole antibody
Source Chimeric/humanized hybrid (mouse/human)
Target TEM1
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C6532H10050N1726O2054S44
Molar mass 147.0 kg/mol

Ontuxizumab[1] is a monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[2]

Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[3]

This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]

References[edit]

  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2). 
  2. ^ Kiyohara, E; Donovan, N; Takeshima, L; Huang, S; Wilmott, J. S.; Scolyer, R. A.; Jones, P; Somers, E. B.; O'Shannessy, D. J.; Hoon, D. S. (2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. PMC 4542822Freely accessible. PMID 26085332. doi:10.1007/s12307-015-0168-8. 
  3. ^ http://adisinsight.springer.com/drugs/800032178
  4. ^ http://adisinsight.springer.com/drugs/800032178